Lauren M B Burke1, Miguel Ramalho1, Mamdoh AlObaidy1, Emily Chang2, Michael Jay3, Richard C Semelka4. 1. Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA. 2. Department of Medicine, Division of Nephrology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA. 3. Department of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA. 4. Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA. Electronic address: richsem@med.unc.edu.
Abstract
PURPOSE: This study aims to describe the self-reporting symptoms experienced by individuals with self-reported normal renal function after gadolinium based contrast agent (GBCA) administration. MATERIALS AND METHODS: This HIPAA-compliant, IRB-approved study consisted of an anonymous online survey of patients who believe that they suffer from gadolinium toxicity. 50 respondents completed the nine-question survey. RESULTS: Fifty (100%) of the subjects ascribed their complaints to gadolinium exposure. Thirty-three (66%) described the onset immediately following GBCA administration and 16 (32%) within 6weeks. The most common symptoms included bone/joint pain and head/neck symptoms including headache, vision change, and hearing change (77.6% each). Other symptoms occurred with lesser incidence. CONCLUSIONS: This survey represents an initial description of patients with normal renal function who self-described toxicity related to GBCA administration. Bone and joint complaints and skin changes are two of the most common complaints.
PURPOSE: This study aims to describe the self-reporting symptoms experienced by individuals with self-reported normal renal function after gadolinium based contrast agent (GBCA) administration. MATERIALS AND METHODS: This HIPAA-compliant, IRB-approved study consisted of an anonymous online survey of patients who believe that they suffer from gadoliniumtoxicity. 50 respondents completed the nine-question survey. RESULTS: Fifty (100%) of the subjects ascribed their complaints to gadolinium exposure. Thirty-three (66%) described the onset immediately following GBCA administration and 16 (32%) within 6weeks. The most common symptoms included bone/joint pain and head/neck symptoms including headache, vision change, and hearing change (77.6% each). Other symptoms occurred with lesser incidence. CONCLUSIONS: This survey represents an initial description of patients with normal renal function who self-described toxicity related to GBCA administration. Bone and joint complaints and skin changes are two of the most common complaints.
Authors: Skorn Ponrartana; Michael M Moore; Sherwin S Chan; Teresa Victoria; Jonathan R Dillman; Govind B Chavhan Journal: Pediatr Radiol Date: 2021-04-19
Authors: Junfeng Wang; Huan Wang; Ian A Ramsay; Derek J Erstad; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale Journal: J Med Chem Date: 2018-09-25 Impact factor: 7.446
Authors: Robert J McDonald; Deborah Levine; Jeffrey Weinreb; Emanuel Kanal; Matthew S Davenport; James H Ellis; Paula M Jacobs; Robert E Lenkinski; Kenneth R Maravilla; Martin R Prince; Howard A Rowley; Michael F Tweedle; Herbert Y Kressel Journal: Radiology Date: 2018-09-11 Impact factor: 11.105